Alexion Pharmaceuticals Inc. (ALXN)

Bespreek hier de kleinere aandelen van de beurs in New York
Plaats reactie
Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 12 Apr 2018 18:59

met m'n 'winst' van balta in gestapt
Alexion Pharmaceuticals has
agreed to buy Sweden's Wilson Therapeutics WTX.ST for 7.1
billion Swedish crowns ($855 million), boosting its line-up of
rare disease drugs as a wave of deal-making in the biotechnology
sector continues.
The U.S. group is acquiring the business through a cash
tender offer worth 232 crowns per share, a premium of 70 percent
compared to the closing share price on April 10.
Alexion was one of the stars of the biotech sector in the
first half of this decade, but it has stumbled more recently
following an exodus of top management and a sales practices
scandal related to Soliris, its pricey rare disease treatment.
Adding Stockholm-based Wilson will give it new therapies to
treat unusual copper-mediated disorders and marks a first step
by the new executive team in overhauling Alexion's medicine
cabinet.
The two companies said on Wednesday that investors holding a
total of 73.4 percent of Wilson's shares supported the takeover
offer.
Shares in Wilson jumped to 230.50 crowns by 1335 GMT, while
Alexion was little changed in early Nasdaq dealings.

The Swedish group's main asset is WTX101, a drug in
final-stage Phase III testing for Wilson disease, a rare genetic
condition that causes severe liver disease and serious
neurological problems. WTX101 works by removing excess copper
from the bloodstream.
"The acquisition of Wilson Therapeutics is a strong
strategic fit for Alexion given the overlap with our current
clinical and commercial focus on metabolic and neurologic
disorders, and is an important first step in rebuilding our
clinical pipeline," said Alexion Chief Executive Ludwig Hantson.
WTX101 has secured fast-track designation in the United
States, which should speed its path to market, and also has
orphan drug status in both the U.S. and Europe, which brings
certain benefits.
SunTrust Robinson Humphrey analyst Yatin Suneja said the new
drug would provide badly needed diversity to Alexion's pipeline,
assuming it proves itself in Phase III. Results from the pivotal
WTX101 trial https://clinicaltrials.gov/ct2/show/NCT03403205 are
expected later next year.
RBC Capital Markets said buying Wilson would use up much of
Alexion's cash pile but there was still scope for smaller deals.
Wilson disease affects approximately 10,000 patients in the
United States and 15,000 in the European Union.

BIOTECH DRUG RACE
There have been a slew of deals in the biotech sector this
year as drugmakers turn to promising drugs from outside to boost
sales growth. Highly priced and high-margin treatments for rare
diseases have been a particular focus for such acquisitions.
On Monday, Swiss drugmaker Novartis agreed to
acquire gene therapy specialist AveXis for $8.7
billion, following similar multibillion-dollar deals by the
likes of France's Sanofi SASY.PA and U.S.-based Celgene
.
Japan's Takeda Pharmaceutical , meanwhile, is
considering a takeover bid for London-listed Shire SHP.L .

Alexion said its acquisition of Wilson was expected to close
in the second quarter of 2018 and that it intended to finance
the acquisition through cash on hand.
Lazard is acting as financial adviser to Wilson, while
Alexion is being advised by BofA Merrill Lynch
piddybull liked last!
Just when you think you've hit rock bottom, someone will hand you a shovel.



josymar
Forum actieveling
Forum actieveling
Berichten: 301
Lid geworden op: 03 Nov 2015 23:35
waarderingen: 89
Contact:

Re: ALEXION PHARMACEUTICALS INC. (ALXN)

Berichtdoor josymar » 12 Apr 2018 19:55

Alexion Pharmaceuticals is een aandeel dat ik principieel (om ethische redenen) nooit zou kopen gezien de zeer "bedenkelijke" politiek van dat bedrijf: geld binnenrijven met alle mogelijke middelen op kosten van de maatschappij. Herinner u het geval Viktor en Solaris in 2013 (zie: https://www.google.com/search?q=viktor+ ... =firefox-b).

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 13 Apr 2018 05:54

ik begrijp je.. maar toch. vervang alexion door gelijk welk bedrijf (ok, er zijn uitzonderingen) en je mag de zin gewoon kopieren.
en al zeker door gelijk welke bank. (banken = legale maffia)
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 23 Apr 2018 10:56

Implications from Soliris patent ruling in Brazil likely immaterial says Alexion
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 26 Apr 2018 16:43

** Drug developer's shares up 6 pct at $113 in
premarket trade
** Alexion Pharma reports better-than-expected Q1 earnings
and positive late-stage study data for rare blood disease
treatment
** Alexion reported earnings of $1.68 per share, beating
analyst estimate of $1.50, according to Thomson Reuters I/B/E/S
** ALXN1210, company's treatment for patients with
paroxysmal nocturnal hemoglobinuria (PNH), was as effective as
its approved treatment Soliris
** Alexion plans to file for regulatory approval for
ALXN1210 in the U.S. and EU in mid-2018, followed by Japan later
in the year
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 27 Apr 2018 07:21

We are very pleased with the strong start to the year and the progress we have made to deliver on our key objectives to drive sustainable, long-term growth.
First, we continued to grow our in-line business from a complement and metabolic portfolios, delivering strong revenue growth, including year-over-year revenue growth of 7% and volume growth of 7%. Second, our Soliris launch for patients with gMG is off to a strong start, particularly in the U.S. and we're on track to meet our ambition of gMG being the best Soliris launch.
Third, today we announced positive data from the 1210 PNH Switch study. Once again, 1210 met a high bar set by Soliris in a second large Phase 3 study. We now have robust data showing that patients with PNH can effectively and safely transition from Soliris to 1210. Based on the totality and consistency of the data from the Phase 3 Naive and Switch studies in a broad patient population, we believe we have a strong, differentiated profile for 1210 and plan to move rapidly through regulatory submissions in the U.S. and EU in mid-2018, followed by Japan later in the year
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 27 Apr 2018 07:22

+14 gisteren
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
Lieve16
Premiummember
Premiummember
Berichten: 3649
Lid geworden op: 02 Jan 2012 22:29
waarderingen: 1725
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor Lieve16 » 27 Apr 2018 09:11

Alexion gives investors a double gift

Finally, shares of Alexion Pharmaceuticals gained 14.5%. The biopharmaceutical company said that revenue for the first quarter of 2018 rose 7% from year-ago levels, helping push adjusted earnings higher by more than 20%. Yet investors really seemed to respond well to news that a phase 3 study of its long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority based on primary and secondary endpoints in patients with a rare blood disease called paroxysmal nocturnal hemoglobinuria. After having had bad luck with some of its pipeline candidate drugs in the past, Alexion investors were pleased to see the company score a promising win.

https://www.nasdaq.com/article/why-domi ... y-cm954375
alles kan beter liked last!

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 25 Mei 2018 07:25

* ALEXION OFFER FOR WILSON THERAPEUTICS ACCEPTED
* ITS OFFER FOR SHARES IN WILSON BEEN ACCEPTED BY
SHAREHOLDERS
REPRESENTING 97.7 PCT OF TOTAL OF SHARES AND VOTES IN WILSON
* ACQUISITION HAS ALSO BEEN APPROVED BY RELEVANT REGULATORY
AUTHORITIES
* TO GIVE WILSON'S SHAREHOLDERS ADDITIONAL TIME TO ACCEPT
OFFER,
CO HAS EXTENDED ACCEPTANCE PERIOD UNTIL JUNE 8, 2018
* TO INITIATE COMPULSORY REDEMPTION PROCEEDINGS REGARDING
REMAINING SHARES IN WILSON AND PROMOTE DELISTING FROM NASDAQ
STOCKHOLM
* OFFER FOR WILSON THERAPEUTICS MADE THROUGH A WHOLLY OWNED
SUBSIDIARY OF CO
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 960
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Alexion Pharmaceuticals Inc. (ALXN)

Berichtdoor alles kan beter » 25 Mei 2018 07:27

Just when you think you've hit rock bottom, someone will hand you a shovel.